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1. Introduction 
Sepsis can be defined as a generalized inflammatory response that occurs during infection 
(Bone et al. 1992) and it seems that a defective host immune system response to a 
microbiological challenge is pivotal in the pathogenesis of septic shock. The pathogenesis of 
sepsis is a result of a complex network of events involving inflammatory and anti-
inflammatory processes, molecular and cellular reactions and circulatory abnormalities 
(Hotchkiss & Karl 2003). Signs and symptoms of sepsis are non-specific for the diagnosis of 
sepsis, but early and appropriate intervention is critical for morbidity and mortality (Levy et 
al. 2005;Rivers et al. 2001). There is a need to find early markers of infection in patients with 
systemic inflammatory response syndrome (SIRS), and also to establish procedures for a 
more accurate risk assessment, predicting patients’ outcome, guiding antibiotic therapy or 
predicting the development of different organ dysfunctions. 
A biomarker is defined as “a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes or pharmacologic responses 
to a therapeutic intervention”(Biomarkers 2001). Countless biomarkers of septic shock have 
been proposed but few or none are currently used in clinical practice or studies. This lack of 
clinical application of research findings is due to several reasons: the lack of “gold standard” 
for the diagnosis, the complex pathophysiology of sepsis, which involves many processes as 
inflammation, immunity, coagulation, etc. Thus, we studied the prognostic value of surface 
molecule expression on lymphocytes and serum levels of the main cytokines, chemokines 
and adhesion molecules to classify the survival of the patients with septic shock. 
First, we demonstrated a severe redistribution of T lymphocyte subsets in patients with 
septic shock. A different kinetic pattern of T cell subset involvement is observed in 
surviving and nonsurviving patients, with lower numbers of circulating CD3+CD8+CD28+ 
and CD3+CD8+CD62L+ cells being associated with a better disease outcome (Monserrat et al. 
2009b). Second, we have also studied the predictive value for outcome of combining 
different T-cell, B-cell and NK-cell markers in septic shock patients. We have found a set of 
five immunophenotypic variables CD3+CD8+CD28+, CD3+CD8+CD45RA+CD45RO-, 
CD19+CD80+, CD56+CD69+, CD3+CD11a br+CD11b+ cells blood counts that improve the 
prediction for outcome in septic shock patients to a sensitivity of 94% and a specificity of 
100% (Monserrat et al. 2009a).  
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In another study of prognostic value of serum mediators, we determined by sandwich 
ELISA the serum levels of proinflammatory cytokines (TNF┙, IL-1┚, IFN┛, and IL-6) and 
soluble cytokine antagonists (sTNF-RI, sTNF-RII, and IL-1Ra) in 52 patients with septic 
shock and in 36 healthy controls at ICU admission and 3, 7, 14, and 28 days later. We 
demonstrated that serum levels of most of the pro- and anti-inflammatory molecules 
examined (TNF┙, IL-6, sTNF-RI, sTNF-RII, and IL-1Ra) were significantly increased upon 
admission and during the 28-day observation period in septic patients when compared to 
controls. Remarkably, the serum levels of anti-inflammatory mediators sTNF-RI, sTNF-RII, 
and IL-1Ra were better predictors of mortality than the levels of proinflammatory cytokines 
(de Pablo et al. 2011). We also measured soluble VCAM-1, ICAM-1, ICAM-2 and PECAM-1 
levels and we demonstrated that they were significantly higher in septic shock patients at 
ICU admission and during the follow-up than in healthy controls. Serum soluble ICAM-1 
was the best biomarker for separating patients with infection from those with non-infectious 
SIRS. On the other hand, soluble E-Selectin found to be a sensitive marker of endothelial 
damage, which may result in multiple organ dysfunction syndrome and death. 
2. Role of peripheral blood lymphocytes in septic shock outcome 
The role of the lymphocytes in the septic shock it’s not clear and it has been studied 
extensively in the last decades (Holub et al. 2000;Holub et al. 2003;Lin et al. 1993;Menges et 
al. 1999;Nishijima et al. 1986). However, there are not many authors that have proposed to 
use lymphocytes as biomarkers for the outcome of these patients (Keane et al. 
1983;Monserrat et al. 2009a). Thus, we decided study the role of the T, B and Natural Killer 
(NK) lymphocytes such as biomarkers in the prediction of the outcome of septic shock 
patients. 
The T cell compartment plays a critical role in regulating the effector stage of the immune 
response. CD3+CD4+ T cells are mainly involved in the regulation of the immune response 
while CD3+CD8+ T cells are critical in the cytotoxic response (Ochoa & Makarenkova 2005). 
Several molecules, mainly the T cell receptor/CD3 complex and other co-receptors 
including CD28, contribute to the activation of T lymphocytes. The expression patterns of 
other molecules, such as the CD45 isoforms RA and RO, vary during the different T cell 
activation effector stages (Hermiston et al. 2003). Activated T lymphocytes show several 
profiles (proinflammatory or anti-inflammatory) of cytokine production (Curfs et al. 1997). 
Other molecules, such as CD62L, participate in the immune response by regulating the 
tissue distribution of the T lymphocytes (Sallusto et al. 1999). Therefore, a role for T 
lymphocytes in severe systemic bacterial infections has been described in several studies, 
and the findings of other investigations have supported the notion that T lymphocytes are 
involved in the pathogenesis of septic shock (Holub et al. 2000;Holub et al. 2003;Kabisch et 
al. 1990;Lin et al. 1993;Nishijima et al. 1986). 
The NK compartment is characterized as CD3-CD56+ cells that can be cytotoxic (CD16+ 
Bright) or produce high amount of cytokines such as IFNγ (CD16+ Dim) (Romagnani et al. 
2007). NK cells are also engaged in crosstalks with other immune cells, such a dendritic cells, 
monocytes, macrophages (Bellora et al. 2010) and neutrophils (Costantini & Cassatella 2011). 
Several lines of evidence suggest that NK cells might be involved in key functions during 
sepsis. During the early stage of septic shock, NK cells may play a key role in the promotion 
of the systemic inflammation as suggested in mice models, but at later stage, NK cells-
acquired dysfunction could favor nosocomial infections and mortality (Chiche et al. 2011). 
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Defects in T and NK lymphocytes are accompanied by alterations in the humoral response. 
The functional consequences of these humoral immune defects are an impaired ability to 
respond to antigens with a rapid and appropriate immune response to microbial antigens 
(Opal et al. 2005). The role of B cells in septic shock is unclear and weakly studied. 
In this first study, we have further characterized the abnormalities of the T cell compartment 
in septic shock and explore its clinical significance. During the first 28 days of follow up 
circulating T lymphocytes of 52 patients with septic shock admitted to the intensive care 
unit (ICU) were analysed and 36 healthy subjects were analysed in parallel. We determined 
the counts and distributions of the main T cell subsets, as well as their stage of activation 
(CD3, CD4, CD8, CD28, 45RA, 45RO and 62L antigens).  
2.1 Patients and methodology 
2.1.1 Patients and study design 
Fifty-two consecutive patients admitted to the ICU of the University Hospital “Príncipe de 
Asturias”, Madrid, Spain, with septic shock, diagnosed according to the criteria of the 
American College of Chest Physicians/Society of Critical Care Medicine (Bone et al. 1992), 
were enrolled in the study. A further requirement was the demonstration of an infectious 
aetiology through microbiological (Gram stain and/or culture) and/or radiological 
techniques, or direct observation of the infection focus. The study protocol did not call for a 
standardised approach to critical care. Exclusion criteria were: anything causing primary or 
acquired immunodeficiency, previous immunosuppressive or immunomodulation 
treatment, cancer, or autoimmune or allergic disease. The study was conducted according to 
the guidelines of the 1975 Declaration of Helsinki, after obtaining the Hospital Universitario 
Príncipe de Asturias Ethics Committee approval. Written informed consent was obtained 
from each subject included in the study or surrogate legal representatives. Thirty-six age-
matched and sex-matched healthy blood donors were studied in parallel with the patients (0 
and 28 days of the follow up). They were studied to control the adequacy of the cytometric 
techniques as well as to characterise the normal range of the T cell compartment parameters 
analysed. 
Blood was collected from these patients at baseline (ICU admission) and at 3, 7, 14 and  
28 days of follow up, and at baseline and at 28 days in healthy controls. White blood  
cell differential counts were conducted in a COULTER®LH instrument (Beckman- 
Coulter Inc). 
2.1.2 Cell separation and surface immunofluorescence 
Peripheral blood mononuclear cells (PBMC) were obtained from heparinised venous blood 
by Ficoll-Hypaque (Lymphoprep Nyegaard) density gradient centrifugation. Cells were 
resuspended (1 x 106 cells/ml) in RPMI-1640 (Biowhittaker Inc.) supplemented with 10% 
heat-inactivated FBS (Cangera International), 25 mM Hepes (Biochrom KG) and 1% 
penicillin streptomycin (Difco Lab). 
T cells were phenotypically analysed in PBMC by four-colour flow cytometry in  
a FACScalibur cytometer using CellQuest software (Becton-Dickinson). PBMC were 
incubated with combinations of fluorescein isothiocyanate (FITC), phycoerythrin (PE), 
peridinin chlorophyll protein (PerCP) and allophycocyanin (APC)-labelled monoclonal 
antibodies. The monoclonal antibodies were CD3-PerCP, CD3-FITC, CD8-PerCP, CD45RA-
FITC, CD56-PE, CD28-PE, CD62L-PE (Becton-Dickinson), CD8-APC, CD45RO-PE (Caltag 
Laboratories). 
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2.1.3 Blood lymphocyte count calculation 
Blood lymphocyte counts of T lymphocyte subsets were calculated according to standard 
flow cytometry criteria for lymphocyte subset identification and the lymphocytes counts 
obtained in conventional haemogram. First, we calculated the percentage of cells expressing 
CD3 in the total lymphocytes gate defined by forward and side scatter in PBMC. Blood 
lymphocyte count of circulatory T lymphocytes was calculated by the percentage of CD3+ 
cells in peripheral blood lymphocytes multiplied by the total number of lymphocytes per 
microlitre measured by a Coulter®. Next, we obtained the absolute number of CD4+ and 
CD8+ T lymphocytes by multiplying the total number of T lymphocytes previously 
calculated by the percentage of positive cells for each one of both antigens in CD3+ T cells. 
We simultaneously stained PBMC with CD3, CD4 and CD8 antibodies to obtain this data. 
Finally, we calculated the absolute number of the CD3+CD4+ and CD3+CD8+ T cells subsets 
defined by the expression of CD45 isoforms CD45RA+CD45RO-, CD45RO+CD45RA-, 
CD45RA+CD45RO+ and the expression of the antigens CD28+ and CD62L+. To calculate 
these numbers, we multiplied the percentage obtained of each subset in the parents’ 
CD3+CD4+ or CD3+CD8+ populations by the absolute count of CD3+CD4+ and CD3+CD8+ T 
cells, respectively. All lymphocyte counts are expressed as cells/µl. 
2.2 Septic shock patients with different outcomes show different patterns of 
circulating T cell subsets 
Blood counts and distributions of the main circulating T lymphocyte subsets were 
systematically examined in 52 patients with septic shock at admission to the ICU and at 3, 7, 
14 and 28 days of follow up in the ICU. Patients were classified as survivors or nonsurvivors 
according to their clinical outcome of sepsis during the four weeks of follow up. Thirty-six 
healthy blood donors who were age-matched and sex-matched (60 ± 3.4 years, 25 men and 
11 women) were studied in parallel with the patients as controls. 
Blood lymphocyte count was 2095±93, 1048±192 and 1235±178 cells/µl in controls, survivors 
and non-survivors respectively. Both, surviving and nonsurviving patients, showed 
significantly lower absolute CD3+ T lymphocyte counts than controls on admission and 
during the first 14 days of follow up. In survivors, CD3+ counts had significantly returned to 
normal by day 28 (Figure 1A). The CD3+CD4+ T cell subset was also reduced in surviving 
and nonsurviving patients with respect to healthy controls at baseline and during the first 
week of follow up. However, this severely decreased CD3+CD4+ T lymphocyte count had 
normalised in survivors by day 14 (Figure 1B). On admission, CD3+CD8+ T lymphocytes 
were also lower in survivors and nonsurvivors than in controls. In survivors, this T cell 
subset showed a further drop on day 3 of follow up, followed by a gradual recovery, 
although numbers failed to reach the count recorded in healthy controls. In addition, 
CD3+CD8+ T lymphocyte count in survivors was significantly diminished with respect to 
nonsurvivors on day 3 (Figure 1C). 
The activation stage of the CD3+CD4+ and CD3+CD8+ T lymphocytes was determined by 
examining the expression of the CD45 RA and RO isoforms. The retraction in circulating 
CD3+CD4+ and CD3+CD8+ T lymphocytes observed in the patients could be mainly 
explained by a decrease in the noneffector CD45RA+CD45RO- subset (Figures 2a,d). 
Interestingly, CD3+CD4+CD45RA+CD45RO- and CD3+CD8+CD45RA+CD45RO- T 
lymphocytes remained low in survivors at the end of follow up. We detected a significant 
decrease in CD3+CD4+CD45RA+CD45RO- T cells on day 3 with respect to the nonsurviving 
patients. CD3+CD4+CD45RA-CD45RO+ T cell counts varied over time from a significant 
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reduction during the first week of follow up to elevated numbers in survivors during the 
last two weeks of the study (Figures 2a,c). The analysis of effector subsets, characterised by 
being double positive (CD45RA+CD45RO+) (Hermiston et al. 2003;Najera et al. 2001), 
showed that were significantly reduced in both CD4+ and CD8+ T lymphocyte subsets at 
baseline, 3 and 7 days in both groups of patients compared with controls and in survivors 
compared with nonsurvivors at 3 days. From day 7 of follow up onwards, these values 
normalised in the surviving patients (Figures 2b,e). 
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Fig. 1. Kinetic of peripheral blood counts of CD3+, CD3+CD4+ and CD3+CD8+ lymphocyte 
subsets in patients with septic shock during their stay in the ICU. Symbol represents: ( ) 
Controls line base, ( ) Survivors and ( ) Nonsurvivors. All values are expressed as 
the mean of cells/µl ± S.E.M. *p<0.05 for survivors or nonsurvivors versus controls; † p<0.05 
for survivors versus nonsurvivors; ‡ p< 0.05 for each follow up time versus admission. 
We also analysed the expression of CD28 and CD62L antigens on CD3+CD4+ and CD3+CD8+ 
T cells. When CD3+CD8+ T cells are activated, CD28 expression is lost (Fiorentini et al. 
2001;Labalette et al. 1999). Number of circulating CD3+CD8+CD28+ T cells was significantly 
and constantly reduced in patients with septic shock compared with the healthy subjects 
and in survivors compared with nonsurvivors during the first three days of follow up 
(Figures 3A, 4). Similar behaviour was shown by CD3+CD8+CD62L+ T cells (Figures 3B, 4). 
Numbers of circulating CD3+CD8+CD28- T cells were normal in both groups of patients. 
A prediction receptor operative curve (ROC) was then used to estimate the value of 
CD3+CD8+CD28+ and CD3+CD8+CD62L+ T cell counts for predicting death in the patients 
with septic shock at admission and days 3 and 7. We found that a cutoff value of 136 
CD3+CD8+CD28+ T cells/ml on admission to the ICU of a patient with septic shock showed 
a sensitivity of 70% and 100% specificity for predicting the risk of death, and the area under 
the ROC curve was 0.84. For the CD3+CD8+CD62L+ T cells, the cut off on admission was 141 
cells/ml, with a 60% sensitivity and 100% specificity for predicting the risk of death and an 
area under the curve of 0.75. The sensitivity and specificity of the data obtained at days 3 
and 7 were worse than those found at admission. 
The number of circulating CD3+CD4+CD28+ T cells was significantly lower in surviving and 
nonsurviving patients with septic shock compared with healthy controls on admission and 
on day 3 of follow-up (Figure 5a). In survivors, this was followed by a gradual recovery of 
CD3+CD4+CD28+ T cell numbers during the course of follow up. CD3+CD4+CD62L+ T cells 
showed a similar pattern of behaviour (Figure 5b). In the parallel study performed in 
healthy blood donors (at 0 and 28 days of the follow up), no significant variations in the 
absolute counts and distribution of the different subsets of T cells analysed were detected. 
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Fig. 2. Kinetic of peripheral blood counts of CD45RA+ and CD45RO+ T lymphocyte subsets 
in patients with septic shock during their stay in the ICU. Symbol represents: ( ) 
Controls line base, ( ) Survivors and ( ) Nonsurvivors. All values are expressed as 
the mean of cells/µl ± S.E.M. *p<0.05 for survivors or nonsurvivors versus controls; † p<0.05 
for survivors versus nonsurvivors; ‡ p< 0.05 for each follow up time versus admission. 
 
 
TIME (days)
0 3 7 14 28
C
D
3
+
C
D
8
+
C
D
2
8
+
 (
c
e
ll
s
/ µ
l)
0
100
200
300
400
* *
*
*
**
*
*
†
† ‡
A
                
TIME (days)
0 3 7 14 28
C
D
3
+
C
D
8
+
C
D
6
2
L
+
 (
c
e
ll
s
/ µ
l)
0
100
200
300
400
* *
**
*
*
‡
*
*‡
† †
B
 
Fig. 3. Kinetic of peripheral blood counts of CD3+CD8+CD62L+ and CD3+CD8+CD62L+ 
lymphocyte subsets in patients with septic shock. Symbol represents: ( ) Controls line 
base, ( ) Survivors and ( ) Nonsurvivors. All values are expressed as the mean of 
cells/µl ± S.E.M. *p<0.05 for survivors or nonsurvivors versus controls; † p<0.05 for 
survivors versus nonsurvivors; ‡ p< 0.05 for each follow up time versus admission. 
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A. Healthy Control                                        CD28                                     CD62L 
 
 
 
 
B. Non Survivor Patient                              CD28                                    CD62L 
 
 
 
 
C. Survivor Patient                                     CD28                                      CD62L 
 
 
Fig. 4. Flow cytometry data analysis of the CD28 and CD62L surface expression in 
CD3+CD8+ T lymphocytes from peripheral blood of septic shock patients 
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Fig. 5. Kinetic of peripheral blood counts of CD3+CD8+CD62L+ and CD3+CD8+CD62L+ 
lymphocyte subsets in patients with septic shock. Symbol represents: ( ) Controls line 
base, ( ) Survivors and ( ) Nonsurvivors. All values are expressed as the mean of 
cells/µl ± S.E.M. *p<0.05 for survivors or nonsurvivors versus controls; † p<0.05 for 
survivors versus nonsurvivors; ‡ p< 0.05 for each follow up time versus admission. 
2.3 Interpretation of blood lymphocyte count alterations in patients with septic shock 
In this study, we show that surviving and nonsurviving patients with septic shock have 
different patterns of involvement in circulating T lymphocyte compartment. A drop in 
circulating CD3+CD4+ and CD3+CD8+ T cells has been described in patients with severe 
sepsis or septic shock at admission to the ICU (Holub et al. 2000;Holub et al. 2003;Kabisch et 
al. 1990;Lin et al. 1993;Nishijima et al. 1986). In our kinetic study, we also observed that this 
T lymphopenia persists during the first week of follow up and is independent of the 
outcome. Moreover, by the end of the second week of follow up, the absolute number of 
circulating CD3+CD4+ T cells had clearly normalised. In contrast, after four weeks of follow 
up, there was still no return to normal circulating numbers of CD3+CD8+ T cells.  
In a mouse sepsis model of caecal ligation and puncture, the depletion of CD3+CD8+ T and 
natural killer cells was associated with a survival benefit with decreased blood bacterial 
concentrations, improved physiological function and an attenuated proinflammatory 
response (Sherwood et al. 2004). It has been reported that mice infected with Plasmodium 
berghei develop a syndrome similar to septic shock and the depletion of CD3+CD8+ T cells 
also significantly ameliorates the complications that induce shock (Chang et al. 2001). In 
addition, in patients with trauma and multiple organ failure (MOF), nonsurvivors showed 
CD3+CD8+ T cell numbers that were two-folds higher than those recorded in survivors 
(Menges et al. 1999). In agreement with these experimental and clinical findings, we 
observed significantly lower CD3+CD8+ T cell counts in survivors compared with 
nonsurvivors on day three of follow up. Thus, diminished circulating CD3+CD8+T cells 
might have a protective pathogenic role in the outcome of septic shock.  
The expression patterns of the RA and RO isoforms of CD45 by T lymphocytes serve to 
identify subsets associated with different stages of T cell activation. When noneffector 
CD45RA+CD45RO- T lymphocytes are activated by inflammatory agents, such as bacterial 
infection, CD45RO is up-regulated and CD45RA down-regulated (Hermiston et al. 2003). 
Thus, our patients showed a persistent reduction in circulating noneffector CD4+CD45RA+ 
CD45RO- and CD8+CD45RA+ CD45RO- T cells. In contrast, numbers of CD8+CD45RA-
CD45RO+ T cells remained normal and CD4+CD45RA-CD45RO+ T cell counts initially fell 
yet had returned to normal by the second week of follow up in surviving patients. An 
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increased percentage of CD3+ cells expressing CD45RO has been reported in patients with 
sepsis (Roth et al. 2003). Our findings could be the consequence of abnormal polyclonal 
activation of circulating T lymphocytes. It has been proposed that the switch of T cells from 
a CD45RA+CD45RO- to a CD45RA-CD45RO+ phenotype may have a functional effect in 
halting the sustained immune response in an effort to avoid tissue injury (Hermiston et al. 
2003). Thus, the expansion of CD4+CD45RA-CD45RO+ T lymphocytes observed here during 
the follow up of surviving patients might be considered a compensatory anti-inflammatory 
mechanism that develops in these patients with septic shock. 
CD28 is a costimulatory molecule that plays a key role in regulating the activation and 
survival of T lymphocytes (Sansom & Walker 2006). Activation of CD3+CD8+ T lymphocytes 
has been related to the loss of CD28 expression (Fiorentini et al. 2001;Labalette et al. 1999). In 
effect, it has been reported that patients with severe sepsis showed a significant reduction in 
T lymphocyte CD28 expression (Manjuck et al. 2000). Our data indicate diminished 
circulating CD3+CD8+CD28+ T cell numbers in patients with septic shock with respect to 
healthy subjects on admission to the ICU and at least during the first 28 days of follow up. 
Interestingly, a reduced CD3+CD8+CD28+ T cell count during the first three days of 
admission to the ICU was of prognostic value for predicting the survival of a patient. 
Conversely, an elevated number of circulating CD3+CD8+CD28+ T cells was associated with 
a worse prognosis for the patient. Recently, it has been reported that the stimulation of 
CD28 by a monoclonal antibody in healthy volunteers is followed by severe multiple 
cytokine-release syndrome (Suntharalingam et al. 2006). Our results support a relevant role 
for CD3+CD8+CD28+ T cells in the pathogenesis of septic shock. Future studies should 
address the potential clinical relevance of this cell variable. 
The migration of circulating T lymphocytes to peripheral lymph nodes depends on the 
expression of the CD62L homing receptor (Tang et al. 1998). We found here that the down-
regulation of L-selectin expression on CD3+CD8+ cells in patients with septic shock was 
associated with a better outcome. Hence, the rapid migration of CD8+ T cells to peripheral 
lymph nodes may be a mechanism contributing to patient survival. 
Our T lymphocyte phenotype data show a time difference, or shift, in the recirculation of T 
lymphocytes between patients who survive septic shock and those who do not. Taken 
together and analysing the phenotype of the circulating T cells according to the activation 
criteria (CD45RA+ and CD45RO+) related to CD28 (activation and co-stimulation) and 
CD62L (activation and migration) expression point to a slower migration of naive and 
effector cells in nonsurviving patients. This different T lymphocyte kinetics would mean a 
delayed tissue response that could determine the failure of the immune system and the fatal 
prognosis of the patient. In particular, the delay in the disappearance of CD45RA+, 
CD45RA+CD45RO+, CD28+, CD62L+, T CD4+ and CD8+ lymphocytes observed between 
days 3 and 7 of follow up in the nonsurvivors appears to be crucial to the final outcome. 
Accordingly, in surviving patients, effectors cells would migrate more rapidly to tissues and 
this would in turn trigger the quick action of the immune system in combating the infection 
and thus determine the survival of the patient. It is known that cellular immune responses 
play a critical role in the defense against viral infections and strong T-cell responses have 
been reported in patients who clear infection (Sarobe et al. 2006a). If the immune response is 
late or less efficient against microorganism viral epitopes, the outcome of the disease 
worsens(Hermiston et al. 2003;Lim et al. 2006;Sarobe et al. 2006b). Not surprisingly, the 
survivor group had lower APACHE II, MODS and SOFA scores than nonsurvivors. An 
increasing APACHE II score reflects an increasing severity of illness and escalating risk of 
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hospital death for multidiagnostic ICU patient groups. However, an APACHE II score 
cannot be directly equated with a specific risk of lower mortality than the same score for a 
patients with septic shock (Wagner et al. 1986). In this group of patients, we found that a 
cut-off value of 136 cells/ml for CD3+CD8+CD28+ T cells and 141 cells/ml for 
CD3+CD8+CD62L+ T cells on ICU admission showed high specificity for predicting the risk 
of death. However, it is known that the positive predictive value for APACHE II for the 
validation study population was only 69.6% and the negative predictive value was 87.9% 
(Joseph E.Parrila & Roger C.Bone 1995). Moreover, SOFA, MODS and APACHE II scores 
require at least 24 hours of monitoring to be performed and lymphocyte phenotyping can be 
performed in a short time, approximately 2 hours. It is not possible to replace clinical score 
in septic shock patients by immunological markers. However, these analytical parameters may 
help to make clinical decisions in these patients and to establish new potential therapeutic 
targets. Future studies will need to study in more depth the mechanisms involved in the 
severe abnormality found on the T cell compartment in patients with septic shock. 
2.4 Cytomics: In the future of the study of cellular biomarkers 
Advances in the knowledge of the immune system has demonstrated the great complexity 
of the T, B and Natural Killer (NK) lymphocyte subsets (Appay et al. 2008). T cell subsets 
display defined immunophenotypic markers at different stages of activation and when they 
have different patterns of tissue migration (Lanzavecchia & Sallusto 2005;Sallusto et al. 
2004). Several pathologic conditions have been associated to different alterations of T cell 
subset distribution (Appay et al. 2008;Wong et al. 2008). In critically ill patients, global T-cell 
responsiveness is typically reduced, reflected in the inability to respond to recall antigens in 
vivo or decreased (Christou et al. 1995) and in impaired lymphocyte proliferation to 
mitogens in vitro (Keane et al. 1983). However, the response to a T-cell-independent 
antigens is preserved or even enhanced (Nohr et al. 1986). Abnormal redistribution of NK 
and B lymphocytes subsets have also been found to be involved in the pathogenesis of other 
diseases (Cerwenka & Lanier 2001;Sanz et al. 2008) but the evidence reported in critical 
illness is less compelling. 
The simultaneous study of different cell subsets distribution can help to translate basic 
knowledge on immune system alterations into clinically and therapeutically relevant 
markers. Our study demonstrates that deeptly characterizing abnormalities on T cell subsets 
can have clinical significance in septic shock (Monserrat et al. 2009b). Thus, we hypothesized 
that the combination of the simultaneous analysis of different immune system cell subsets 
would improve the prediction of outcome in septic shock patients. In addition to the results 
described previously in our work and following a cytomics analysis, we have also studied 
the predicting value for outcome of combining different T, B and NK cell markers in the 52 
septic shock patients reported in our article (Monserrat et al. 2009b). 
 Cytomics is an innovative mathematic and statistic bioinformatics analysis procedure 
(similar to data mining studies) of multiple cellular variables obtained from a population of 
patients (Valet G.V. et al. 1998;Valet et al. 1993;Valet 2002). Cytomics allows to select a set of 
multiple quantitative biological variables able to improve the accuracy of patient prognosis 
and/or establish a predictive value of response to an optional treatment (Valet & Tarnok 
2003). Cytomics studies have been previously applied to different fields in medicine: 
intensive care (Rothe et al. 1990;Valet G.V. et al. 1998), oncology/hematology (Valet et al. 
2003;Valet & Hoeffkes 2004), or autoimmune diseases (Jacobi et al. 2003); moreover a human 
cytome project is underway (Valet et al. 2004;Valet & Valet 2005). 
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Following the methods and flow cytometry technique described previously (section 2.1.2-
2.1.3), we quantified the absolute number of circulating CD3+, CD4+, CD8+, CD19+ and 
CD56+ lymphocytes and their subsets defined by the co-expression of one, two or three of 
the following antigens: CD69+, HLA-DR+, CD25+, CD26+, CD38+, CD45RA+, CD45RO+, 
CD71+, CD23+, CD57+ as activation markers, CD80+, CD86+, CD40L+ and CD40+ as co-
stimulation markers and CD11a+, CD11b+, CD11c+, CD31+, CD62L+,CD29+ as adhesion 
markers and CD95+ as apoptosis marker. This cellular quantification was performed in each 
patient at ICU admission and the clinical outcome was analyzed over a 28-day period. The 
absolute numbers of the different lymphocyte subsets obtained in each patient were 
introduced in a database. Symmetrical upper and lower threshold percentile values (low 
percentile 33 and high percentile 67) were selected according to the mortality in our series of 
patients. These thresholds were used to re-express individual data-base values into +, 0 or – 
according to their position above, within or below the respective reference percentile 
thresholds as described (Valet G.V. et al. 1998;Valet et al. 1993). Receiver operating 
characteristics (ROC) curves were built for each phenotypic variable. The sensitivity  
and specificity of each variable to predict the real outcome was thus obtained (McNeil & 
Hanley 1984;Metz 1978). The variables with higher sensitivity values were selected and 
combined to create multiple variable combinations or masks. The mask with the highest 
sensitivity and specificity prediction ability for outcome was selected to define the 
combinations of cut-off values for each variable. According to this methodology we have 
found a set of five variables and their cut off values (showed in table 1) that are able  
to improve the prediction for outcome on septic shock patients to a sensitivity of 94 per cent 
and a specificity of 100 per cent. 
 
MASK SUBSET Nº/µl 
CD56+CD69+ >114 
CD3+CD8+CD45RA+CD45RO- >114 
CD3+CD8+CD28+ >163 
CD19+CD80+ >67 
CD3+CD11A BR+CD11B+ >250 
Table 1. Final Mask results after a cytomics study: represent the cut off count of lymphocytes 
subsets by microlitter that can be able to predict the fatal outcome of the shock septic 
patients. 
These results support the notion that the immune phenotypical analysis of different 
circulating lymphocyte subsets in septic shock patients has a relevant prognostic value. 
Leukocyte phenotyping might also have predictive value for the development of immune-
supportive or immuno-stimulatory therapies in the management of septic shock patients. 
The analysis of the abnormalities in the distribution of the T cell compartment in critical 
patients outside septic shock could also be of great interest (McDunn et al. 2009). We have 
applied in parallel the immunophotypical T lymphocyte protocol described here to severe 
acute pancreatitis and ischemic myocardial infarct patients. Our results showed that the 
patterns of alteration of the distribution and activation stage of T cell subsets are not 
homogenous in these different acute severe diseases. Thus, the potential involvement of T 
cell compartment in the pathogenesis of septic shock requires further research and raises the 
development of innovative diagnostic and therapeutic strategies in these patients. 
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3. Role of the serum molecules in septic shock 
3.1 Diagnosis of sepsis 
Numerous putative markers of sepsis have been studied: microbial products, physiologic 
parameters, hematopoietic cells, cell surface markers, soluble receptors, cytokines, acute 
phase reactants, mediators of coagulation, cellular processes and others like procalcitonin 
(Marshall et al. 2003). Probably, procalcitonin is the most extensive laboratory marker used 
for the discrimination of sepsis in patients with SIRS. In 2001, the 
SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference included 
plasma procalcitonin above 2SD of the normal value into the diagnostic criteria for sepsis 
(Levy et al. 2003). They also included plasma C-reactive protein as a criterium for sepsis, but 
most studies found procalcitonin to be superior to C-reactive protein (Uzzan et al. 2006). We 
also found these findings and we demonstrate that procalcitonin in combination with 
Sequential Organ Failure Assessment (SOFA Score) (Vincent et al. 1998) was useful to 
diagnose infection (Ruiz-Alvarez et al. 2009). However, in newborns, immunosuppressed or 
elderly patients, procalcitonin had not been shown to be a great asset in the diagnosis of 
sepsis. Moreover, little is known about serum procalcitonin levels in renal failure and 
evidence suggests that it is dialyzed (Dahaba et al. 2003). 
The release of inflammatory cytokines, such TNF┙, IL-1┚, IL-6, IL-8 and IFN┛ in response to 
infection leads to SIRS and MOF. Probably, the cytokine that longer has been investigated as 
a marker of infection is IL-6. IL-6 can be measured reliably in the blood after insult to the 
host, but it is relatively nonspecific of infection and is elevated in other inflammatory states. 
When serum IL-6 levels were measured to assess the diagnostic value of infection in patients 
with SIRS, procalcitonin was superior to IL-6 (Harbarth et al. 2001). 
Vascular endothelium injury is widely recognized to play a critical role in many systemic 
inflammatory diseases as sepsis. However, the ability of the measurement of soluble 
adhesion molecules to distinguish infection in SIRS patients has been poorly investigated. 
Bold et al. demonstrated that trauma patients showed lower plasma levels of circulating 
adhesion molecules than did sepsis patients indicating more pronounced endothelial 
activation or damage in sepsis (Boldt et al. 1996). Cummings et al. reported that soluble E-
selectin levels are higher in serum of patients with microbiologically documented sepsis 
than in other critically ill patients (Cummings et al. 1997). Recently, we also studied 
circulating soluble adhesion molecules levels in 92 patients with SIRS and demonstrated 
that sICAM-1 was a better biomarker of infection than sE-Selectin, sVCAM-1 and sICAM-2. 
An acute-phase proteins has been defined as one whose plasma concentrations increases or 
decreases by at least 25% during inflammatory disorders (Gabay & Kushner 1999). 
Lipopolysaccharide-binding protein (LBP) is considered an acute-phase protein. It is 
synthesized by hepatocytes and intestinal epithelial cells and its concentrations rising up 
after induction of an acute-phase response. A very interesting issue by Albillos et al. 
analyzed the risk factors associated with a first episode of severe bacterial infection in 84 
ascitic cirrhotics. Increased LBP was the only factor independently associated with severe 
bacterial infection in a multivariate analysis (relative risk 4.49, 95% CI 1.42-14.1). The 
authors suggested that monitoring of serum LBP could, therefore, help to target cirrhotic 
patients with ascites for antibiotic prophylaxis (Albillos et al. 2004). However, LBP 
measurements in ICU patients with SIRS and sepsis have not been found any benefit 
(Prucha et al. 2003), except in selected patient populations as heart surgery, neonates or 
neutropenic patients (Pavcnik-Arnol et al. 2004;Sablotzki et al. 2001).  
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Phagocytic cells are the primary mediators of the innate immune response to bacterial and 
fungal infections. Triggering receptor expressed on myeloid cells-1 (TREM-1) is a member of 
the immunoglobulin family and is upregulated in response to infection acting 
synergistically with Toll-like receptor-4 to augment the immune response. TREM-1 may be 
not upregulated in noninfectious inflammatory disorders. A soluble form of TREM-1 
(sTREM-1) is shed from the membranes of activated phagocytic cells and can be quantified. 
Studies conducted in ICUs indicated that sTREM-1 is more specific and sensitive than either 
procalcitonin or C-reactive protein (Bouchon et al. 2001;Gibot et al. 2005). However, in a 
recent study in patients admitted in a surgical ICU, measurement of sTREM-1 did not 
distinguish between patients with SIRS, severe sepsis, or septic shock (Bopp et al. 2009). 
Finally, a recent study only 10 biomarkers have been assessed for their ability to distinguish 
septic from non-septic patients with SIRS, but no biomarker was clearly identified as being 
able to differentiate infection in SIRS from other causes (Pierrakos & Vincent 2010).  
3.2 Risk assessment and severity 
A severity marker provides information about whether a patient with sepsis will experience 
an adverse outcome. Classical illness scores, such as Acute Physiology and Chronic Health 
Evaluation (APACHE) and Simplified Acute Physiology Score (SAPS), can predict the 
severity and outcome of sepsis. Relatively few biomarkers have been evaluated to establish 
risk assessment and severity in sepsis. Plasma procalcitonin concentrations correlated to 
sepsis-related organ failure scores and may be useful in risk assessment (Meisner et al. 1999). 
In 2007, the FDA approved the use of procalcitonin in conjunction with other laboratory 
findings and clinical assessments to aid in the risk assessment of critically ill patients on their 
first day of ICU admission for progression to severe sepsis and septic shock. 
On the other hand, it has been reported that IL-2 and IL-8 increased in parallel with disease 
severity (Balcl et al. 2003) and anti-inflammatory cytokines as IL-4, IL-10 and IL-13 have 
higher concentrations in patients with sepsis than in patients with septic shock (Collighan et 
al. 2004;Heper et al. 2006). It is important to remark that the production of anti-
inflammatory cytokines during septic shock correlates positively with the intensity of the 
inflammatory response and, as we will describe later, with fatal outcome. 
The severity of septic reaction varies a lot in course and outcome depending on host 
predisposing factors, the infection characteristics, the intensity of host response and, 
finally, the number of organs failing. The PIRO staging model based on these factors 
could better predict outcomes of patients with sepsis (Rubulotta et al. 2009). The risk of 
dying from an infectious disease is much more depend on genetic than on environmental 
factors (Sorensen et al. 1988). Genetic polymorphisms in innate immunity result in 
significant interindividual variability in response to infection. In the last years, more than 
30 genes have had their respective polymorphisms studied for relations to sepsis and 
critical infection or inflammation (Namath & Patterson 2009). Sepsis-related 
polymorphism studies have most commonly focused on one or more polymorphisms for 
specific genes whose protein products are implicated in sepsis. Current studies include 
genome-wide approaches, which analyze large representative sets of genetic markers 
derived from the human haplo-type map in search of those markers associated with a 
chosen phenotype. New techniques enable detection of thousands of single nucleotide 
polymorphisms in a single patient, which promise new insights into genetics variations 
(Marshall & Reinhart 2009).  
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3.3 Guide of therapy 
A biomarker may also aid to guide therapy. First, we need a reliable diagnostic laboratory 
test that indicates that a clinical syndrome of systemic inflammatory response is likely due 
to a bacterial or fungal infection. Prompt appropriate empirical antibiotic therapy, searching 
and controlling infection source, hemodynamic and adjuvant therapy must be initiate as 
soon as possible for improving survival in patients with sepsis. Conversely, if infection is 
unlikely to be present permits the clinician to discontinue antibiotics and therefore a 
minimization of the adverse events. Second, a biomarker may help us to administer 
therapies to the right patients at the right time. A biomarker whose levels changes during 
ICU stay may provide information to monitor the response to treatment. In patients with 
sepsis, an increase or decrease in one marker levels may reflect that the patients responds or 
fails to respond. Third, critically ill patients with SIRS are a heterogeneous population of 
patients. A biomarker may also aid to distinguish patterns of a homogeneous group of 
patients, in whom the benefit of a therapy is known or could be investigated. Fourth, rapid 
diagnosis of reduced levels of a critical factor or elevated levels of a specific target may be of 
interest for the rational use of therapies (Cohen et al. 2001). 
There are many more potential biomarkers for sepsis than are currently used in clinical 
studies. IL-6 levels of more than 1000 ng/ml were reported to be highly predictive of sepsis-
related death (Harbarth et al. 2001). This finding was used to identify patients more severe 
who would benefit from adjuvant treatments. However, the results from a large multicenter 
study randomized patients with severe sepsis to treatment with antibody against TNF or 
placebo, stratifying patients on the basis of baseline levels of IL-6 have proven disappointing 
(Panacek et al. 2004).  
Several studies have investigated the use of procalcitonin as a marker of treatment 
strategies. Recently, a meta-analysis which included seven randomized controlling studies 
reporting on antibiotic use and clinical outcomes of 1131 ICU patients managed with a 
procalcitonin-guided algorithm or according to routine practice has been published. The 
main results are: 1) decreased antibiotic exposure; 2) similar mortality rates and ICU or 
hospital length of stay; and 3) comparable rates of superinfection and persistent or relapsed 
infection. 
C-reactive protein is often reported as inferior compared with procalcitonin as a marker, but 
it is frequently used in clinical practice because of its greater availability. Serial monitoring 
of C-reactive protein levels may have some value in predicting infection and response to 
antibiotics in the ICU (Povoa et al. 2006;Schmit & Vincent 2008). 
3.4 Predicting development of organ dysfunction 
It is known that the severity of organ failure has significant impact on the prognosis of 
patients with sepsis. Numerous biomarkers were assessed for their ability to predict the 
development of MOF. We focused our investigation on the possible association between 
different organ failures and serum concentrations of soluble cytokines and their soluble 
receptors in patients with septic shock (de Pablo et al. 2011). The overall prevalence of organ 
dysfunction at ICU admission was 46% for acute respiratory distress syndrome (ARDS), 
36% for acute renal failure (ARF) and 19% for coagulation failure (DIC). Circulating IL-10, 
sTNF-RI, sTNF-RII, IL-1Ra concentrations were significantly higher in patients with ARDS, 
ARF and DIC at the time of patients’ entry in the study. Serum TNF┙ levels were found 
higher in sepsis-induced ARF or DIC. IL-6 was higher in ARDS patients than in patients 
with septic shock without ARDS. However, there were no significant differences in serum 
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levels of IL-1┚, IFN┛ or TGF-┚ than septic patients without these organ failures. TGF-┚ is a 
cytokine that plays a pivotal role mainly in the tissue repair reaction subsequent to 
inflammatory response. It is interesting to remark that in patients with septic shock and 
persistent ARDS, TGF-┚ levels are increased. These high concentrations at day 7 of follow-
up are related to MOF and death (Figure 6)(de Pablo et al. 2006c). 
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Fig. 6. Serum TGF-β levels in septic shock patients.* p<0.05 between patients with or without 
ARDS, † p<0.05 between survivors and nonsurvivors. Data are expressed as mean ± S.E.M. 
When the patients had failure in two or more organ system, they were considered as 
multiple organ dysfunction syndrome (MODS). Once again, anti-inflammatory molecules 
such as IL-6, IL-10, sTNF-RI, sTNF-RII, IL-1Ra and sIL-2R were elevated in patients with 
MODS, but not pro-inflammatory cytokines: TNF┙, IL-1┚, IFN┛ or chemokines: IL-8, MCP-1, 
MIP-1┙ or RANTES (table 2). 
 
 With MODS Without MODS  With MODS Without MODS 
IFNγ 9.17±3.01 15.13±5.59 IL-10 5.57±1.98 35.95±20.42* 
TNFα 14.42±2.97 36.12±10.83 IL-2R 4584±235 5724±417* 
IL-1β 2.10±0.84 2.15±0.80 TGF-β 40.06±6.67 31.04±4.18 
IL-6 1267±672 2737±663* IL-8 206±157 339±116 
sTNF-RI 3673±500 5042±617* MCP-1 2797±1049 2997±572 
sTNF-RII 4984±558 6373±724* MIP-1α 61.94±15.50 66.42±13.90 
IL-1 ra 7099±1464 11052±2030* RANTES 20177±3831 15325±2140 
Table 2. Serum cytokines and chemokines levels in septic shock patients with or without 
MODS at ICU admission.* p<0.05 between patients with or without MODS. Data are 
expressed as mean ± S.E.M. 
3.5 Prognosis 
Sepsis, severe sepsis and septic shock are the leading cause of death in critically ill patients 
(Hotchkiss & Karl 2003). The ICU mortality rates increase with the severity of the syndrome: 
27% for sepsis, 32% for severe sepsis and 54% for septic shock (Vincent et al. 2006). Outcome 
from sepsis in terms of mortality is not only associated with the amount of organ 
dysfunction developed (Alberti et al. 2003). Other variables as age, genetic backgrounds, 
comorbidities, reasons for ICU admission, and related to infection (acquisition, extension, 
site and agent) were observed in outcome of patients with sepsis (Gustot 2011). PIRO system 
emerged from the Fifth Toronto Sepsis Roundtable. It includes Predisposition, Injury, 
Response and Organ Dysfunction (Marshall et al. 2003). However, this approach remained 
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up to now virtually conceptual and other research groups empirically developed in cohorts 
of patients a scale for predicting mortality in sepsis (Moreno et al. 2008). 
Sepsis biomarkers may contribute to this model of classification. However, at this moment 
the majority of the biomarkers have been evaluated as prognosis markers and in our search, 
we assessed the ability of a biomarker to differentiate patients likely to survive from those 
likely to die. We studied by sandwich ELISA serum levels of pro-inflammatory cytokines 
(TNF┙, IL-1┚, IL-6 and IFN┛), anti-inflammatory cytokines (IL-10 and TGF┚) and soluble 
cytokine antagonist (sTNF-RI, sTNF-RII and IL-1Ra) during the first 28 days of ICU 
admission in 52 patients with septic shock. We found that serum an early response to 
continuously elevated soluble sTNF-RI, sTNF-RII and IL-1Ra serum levels was associated 
with an enhanced risk of fatal outcome (table 3). ROC analysis revealed that sTNF-receptor I 
or sTNF receptor II concentrations over 2767 or 4619 pg/ml, respectively, determinate a 
high risk of death. The sensitivity-specificity for sTNF-RI was 100%-57% and for sTNF-RII 
was 100%-71%. IL-1Ra concentrations below 7033 pg/ml determined a high probability of 
survival (sensitivity-specificity of 60-100%). 
 
 Survivors Nonsurvivors  Survivors Nonsurvivors 
IFNγ 16.59±5.90 7.16±2.07 IL-10 7.38±3.43 57.39±35.71* 
TNFα 23.81±7.42 40.42±17.91 IL-2R 4830±183 6177±661 
IL-1β 1.78±0.51 2.75±1.38 TGF-β 33.74±4.06 33.38±5.57 
IL-6 1960±609 2811±931 IL-8 265±113 356.7±167.7 
sTNF-RI 3910±396 6050±1043* MCP-1 3020±670 2774±771.7 
sTNF-RII 4862±430 8005±1074* MIP-1α 67.7±12.9 59.3±18.6 
IL-1 ra 7331±1351 3819±2880* RANTES 14758±2105 20714±3624 
Table 3. Serum cytokines and chemokines levels in septic shock patients at ICU admission. 
*p<0.05 between survivors and nonsurvivors. Data are expressed as mean ± S.E.M. 
Serum levels of TNF┙, IL-1┚, IL-6 were significantly elevated on admission and during the 
28 days of follow-up in septic patients when compared with healthy controls, but were not 
predictors of mortality (table 3). Interestingly, IFN┛ levels were significantly higher in 
survivors than in controls during the initial two weeks of observation (de Pablo et al. 2011). 
Serum IL-10 concentrations were elevated in the first 3 days in non-survival patients. TGF┚, 
an anti-inflammatory cytokine capable of converting an active site of inflammation into one 
dominated by resolution and repair (Letterio & Roberts 1997), discriminated patients with 
fatal outcome at day 7 of the follow-up (Figure 6). All these findings together suggest that 
mortality in patients with septic shock correlates more with anti-inflammatory molecules 
than with pro-inflammatory immunomodulatory molecules. Many previous clinical trials 
have failed to show benefit using anti-inflammatory agents, because the inflammatory status 
of the patients is a dynamic process where it may be reasonable to test the hypothesis of 
using immunoinflammatory stimulation therapy on patients with septic shock with high 
risk of death determined by the presence in blood of high levels of  sTNF-RI, sTNF-RII and 
IL-1Ra or low of IFN┛. We also studied the prognostic value of chemokines and soluble 
adhesion molecules. Chemokines are a large superfamily of small peptides that are key 
participants to not only control of leukocyte trafficking, but necessary for the linkage 
between innate and adaptative immunity. No significant differences were found between 
survivors and nonsurvivors at any time of the follow-up in serum levels of IL-8, MCP-1, 
MIP-1 and RANTES (table 3) (de Pablo et al. 2006b). 
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Next, we focused our investigation in the prognostic value of fatal outcome of the 
circulating soluble adhesion molecules in the population of patients with septic shock 
admitted at the ICU. Mortality was defined as death occurring within 28 days after study 
enrolment. At ICU admission, serum soluble E-Selectin concentrations showed significantly 
higher levels in the nonsurvival group (110.08±8.00ng/ml) than in survival group 
(88.73±4.92ng/ml; p=0.041). We also analysed serum E-Selectin levels at ICU admission as a 
predictor of outcome, determining the area under the receiver operating characteristics 
curve (AUC). The AUC value for baseline measurements of E-Selectin was 0.728 (p=0.049; 
95% confidence interval, 0.516-0.939). Thus, an E-Selectin concentration of 106.8ng/ml was 
identified as the optimum threshold to distinguish the patients for outcome with a 
sensitivity of 60.0% and specificity of 85.7%. Over the study period, no significant change in 
circulating soluble VCAM-1, ICAM-1, ICAM-2 and PECAM-1 concentrations was observed 
between survival and nonsurvival patients. Thus, soluble E-Selectin is a marker of 
endothelial damage, which may result in failure of the different organs, multiple organ 
dysfunction syndrome and death (de Pablo et al. 2006a). 
Numerous biomarker have been reported in prognosis like other cytokines as IL-12 or IL-18, 
cell markers as soluble HLA-DR, receptors as TREM-1 or as urokinase type plasminogen 
activator receptor, related to vascular endothelial damage as von Willebrand factor and 
antigen or like acute phase proteins as ferritin or procalcitonin (Pierrakos & Vincent 2010). 
However, no biomarker has established itself sufficiently to be of help in clinician practice. 
Each biomarker has limited sensitivity and specificity; therefore, it may prove more useful 
to combine various markers. Biomarker panels or composite markers may prove most useful 
in examining a particular immunologic pathway, identifying at-risk individuals who require 
aggressive intervention, predicting organ response and determining the ability to 
differentiate patients likely to survive from those likely to die (Ventetuolo & Levy 2008). 
4. Conclusion 
Many biomarkers have been evaluated for the use in sepsis, many more than in other disease 
processes. At present, around of 178 different biomarkers were actually evaluated in the 3370 
studies, 77 in experimental studies and 101 in clinical studies only, 58 in both experimental and 
clinical studies (Pierrakos et al. 2010). However, hardly a few of them are able to report 
sensitivity and specificity values greater than 90%. We demonstrated that septic shock patients 
show a severe redistribution of circulating T lymphocyte subsets and CD62L and CD28 
expression on circulating T cells at ICU admission are good markers to predict the outcome of 
shock septic patients. We found that T lymphocyte phenotype data show a time difference in 
the recirculation of T cells between survivors and nonsurvivors that might provoke a delayed 
tissue response of the immune system. Moreover, we demonstrated that the simultaneous 
analysis of different immune system cell subsets in combination like (CD56+CD69+, 
CD3+CD8+CD45RA+CD45RO-, CD3+CD8+CD28+, CD19+CD80+, CD3+CD11A BR+CD11B+) would 
improve the prediction of outcome in septic shock patients. With respect to serum cytokines, 
we found that antiinflammatory and adhesion molecules are good markers for the prognosis 
of septic shock patients. We propose that the blood counts of circulating cells of the immune 
system are good candidates to study for value as biomarkers. In this book chapter we attempt 
to resume the continuous effort by clinician and researchers to find new biomarkers that going 
to allow us to improve the prognostic of septic shock patients. New experiments and clinical 
studies are necessary to achieve this goal. 
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